Echinocandin-resistant Candida: Molecular methods and phenotypes

Current Fungal Infection Reports

Volumn 5, Issue 3, 2011, Pages 113-119

  Perlin, David S ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Anidulafungin; Candida albicans; Candida glabrata; Caspofungin; Clinical breakpoint; Echinocandins; Epidemiologic cutoff value; FKS; Glucan synthase; Micafungin; Resistance

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; GLUCAN SYNTHASE; MICAFUNGIN;

AMINO ACID SUBSTITUTION; ANALYTIC METHOD; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; DRUG POTENCY; FKS GENE; FUNGAL GENE; FUNGAL STRAIN; FUNGUS ISOLATION; GENOTYPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; RELIABILITY; REVIEW; WILD TYPE;

EID: 80755153763     PISSN: 19363761     EISSN: 1936377X     Source Type: Journal    
DOI: 10.1007/s12281-011-0054-x     Document Type: Review

References (50)

1. Kartsonis N, DiNubile MJ, Bartizal K, et al. Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. J Acquir Immune Defic Syndr. 2002;31:183-7. (Pubitemid 35190573)
2. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472-82. (Pubitemid 46919773)
3. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45:883-93. (Pubitemid 47580382)
4. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41:654-9. (Pubitemid 41170353)
5. Maertens J, Egerer G, Shin WS, et al. Caspofungin use in daily clinical practice for treatment of invasive aspergillosis: results of a prospective observational registry. BMC Infect Dis. 2010;10:182.
6. Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer. 2010;55:229-32.
7. Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother. 2005;49:4536-45. (Pubitemid 41552583)
8. Vazquez JA. The safety of anidulafungin. Expert Opin Drug Saf. 2006;5:751-8. (Pubitemid 44669490)
9. Kurtz MB, Douglas CM. Lipopeptide inhibitors of fungal glucan synthase. J Med Vet Mycol. 1997;35:79-86. (Pubitemid 27174580)
10. Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother. 2002;46:3001-12.
11. Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol. 2003;41:5729-31. (Pubitemid 37543273)
12. Bachmann SP, Patterson TF, Lopez-Ribot JL. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance. J Clin Microbiol. 2002;40:2228-30. (Pubitemid 34596413)
13. Ramage G, Saville SP, Wickes BL, et al. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002;68:5459-63. (Pubitemid 35265681)
14. DenningDW. Echinocandin antifungal drugs. Lancet. 2003;362:1142-51. (Pubitemid 37222342)
15. Perlin DS. Resistance to echinocandin-class antifungal drugs. Drug Resist Updat. 2007;10:121-30. (Pubitemid 47031054)
16. Pfaller MA, Diekema DJ, Andes D, et al. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at speciesspecific interpretive criteria. Drug Resist Updat. 2011, Feb 23 (Epub ahead of print). This critical report summarizes data used by the CLSI to establish revised clinical breakpoints for echinocandin susceptibility and resistance.
17. Perlin DS. Current perspectives on echinocandin class drugs. Future Microbiol. 2011;6:441-57.
18. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46:150-6.
19. Pfaller MA, Boyken L, Hollis RJ, et al. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J Clin Microbiol. 2010;48:52-6.
20. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46:2620-9.
21. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J Clin Microbiol. 2011;49(2):624.
22. This is a comprehensive global surveillance study identifying non-wild-type clinical isolates by species and drug.
23. Arendrup MC, Bruun B, Christensen JJ, et al. National surveillance of fungemia in Denmark (2004 to 2009). J Clin Microbiol. 2011;49:325-34.
24. Pfaller MA, Moet GJ, Messer SA, et al. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2011;55:561-6.
25. Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother. 2010;54:5042-7.
26. Castanheira M, Woosley LN, Diekema DJ, et al. Low prevalence of fks1 hot spot 1 mutations in a worldwide collection of Candida strains. Antimicrob Agents Chemother. 2010;54:2655-9.
27. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1, 3-beta-D-glucan synthase. Proc Natl Acad Sci USA. 1994;91:12907-11.
28. Mazur P, Morin N, Baginsky W, et al. Differential expression and function of two homologous subunits of yeast 1, 3-beta-D-glucan synthase. Mol Cell Biol. 1995;15:5671-81.
29. Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1, 3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690-9.
30. Mazur P, Baginsky W. In vitro activity of 1, 3-beta-D-glucan synthase requires the GTP-binding protein Rho1. J Biol Chem. 1996;271:14604-9. (Pubitemid 26190367)
31. Frost D, Brandt K, Estill C, et al. Partial purification of (1, 3)-beta-glucan synthase from Candida albicans. FEMS Microbiol Lett. 1997;146:255-61. (Pubitemid 27057731)
32. Garcia-Effron G, Park S, Perlin DS. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob Agents Chemother. 2009;53:112-22. This comprehensive evaluation of fks mutant genotypes, MIC, and kinetic inhibition of glucan synthase from C. albicans reveals the need to reassess the initial clinical breakpoint.
33. Pratt A, Garcia-Effron G, Mustaev A, et al. Evaluation of fluorescent labeled caspofungin for fungal identification [abstract]. Presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010). Boston, MA, September 12-15, 2010.
34. Paderu P, Park S, Perlin DS. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob Agents Chemother. 2004;48:3845-9. (Pubitemid 39304613)
35. Cowen LE. Hsp90 orchestrates stress response signaling governing fungal drug resistance. PLoS Pathog. 2009;5:e1000471.
36. Kartsonis N, Killar J, Mixson L, et al. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome. Antimicrob Agents Chemother. 2005;49:3616-23. (Pubitemid 41233008)
37. Pfaller MA, Diekema DJ, Boyken L, et al. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother. 2005;49:4795-7. (Pubitemid 41552623)
38. Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother. 2005;49:3264-73. (Pubitemid 41060570)
39. Katiyar S, Pfaller M, Edlind T. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50:2892-4. (Pubitemid 44198725)
40. Slater JL, Howard SJ, Sharp A, et al. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob Agents Chemother. 2011, in press.
41. Andes DR, Diekema DJ, Pfaller MA, et al. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52:3497-503.
42. Andes D, Ambrose PG, Hammel JP, et al. Use of pharmacokineticpharmacodynamic analyses to optimize therapy with the systemic antifungal, micafungin, for invasive candidiasis or candidemia. Antimicrob Agents Chemother. 2011;55:2113-21.
43. Andes D, Diekema DJ, Pfaller MA, et al. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother. 2010;54:2497-506.
44. Desnos-Ollivier M, Bretagne S, Raoux D, et al. Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing. Antimicrob Agents Chemother. 2008;52:3092-8.
45. Arendrup MC, Park S, Brown S, et al. Evaluation of caspofungin and micafungin CLSI M44-A2 Disk Diffusion and associated breakpoints testing using a well characterized panel of wild type and fks hot spot mutant Candida isolates. Antimicrob Agents Chemother. 2011;55:1891-5.
46. Garcia-Effron G, Park S, Perlin DS. Improved detection of Candida spp. fks hot spot mutants using the CLSI M27-A3 Document by the addition of Bovine Serum Albumin (BSA). Antimicrob Agents Chemother. 2011;55:2245-55.
47. Arendrup MC, Rodriguez-Tudela JL, Park S, et al. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob Agents Chemother. 2011;55:1580-7.
48. Perlin DS. Antifungal drug resistance: do molecular methods provide a way forward? Curr Opin Infect Dis. 2009;22:568-73.
49. Balashov SV, Park S, Perlin DS. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob Agents Chemother. 2006;50:2058-63. (Pubitemid 43807526)
50. Ben-Ami R, Garcia-Effron G, Lewis RE, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis. 2011, in press.